Inovio Pharmaceuticals Stock News

Moderna’s stock is down today after CEO Stephanie Bancel told CNBC the company plans to slow its enrollment of its clinical vaccine trial to ensure it has sufficient representation of minorities at

These businesses are backed by science, and they've already got orders lined up for their experimental vaccines.

Taking a looking at the COVID-19 vaccine development landscape across various classes, including viral vectors, genetic vaccines, recombinant protein vaccines, attenuated virus vaccines, inactivated v

Former White House Physician Jennifer Pena speaks with Yahoo Finance's Zack Guzman about the CDC telling states to be ready to distribute a coronavirus vaccine on November 1.

Numerous well-funded coronavirus vaccines are rapidly proceeding through clinical trials. INO stock risks being left behind.

Short-sellers are betting against these stocks big time. But that could set up big opportunities for investors if these biotechs have positive news on the way.

The biotech company continues to give up the gains it earned earlier this year.

Inovio Pharmaceuticals Inc. shares INO, -7.88% slid 8% Wednesday, after Muddy Waters said it has taken a short position in the stock, which has been boosted this year by high hopes for its COVID-19 va

The first time I highlighted opportunity in Inovio Pharmaceuticals (NASDAQ:INO), it traded at just $4.86 a share. That was in late January.

The huge amount of Operation Warp Speed funding for its six vaccines has helped them become somewhat dominant leaders in the race for a sizable share of the market.

One of these high-flying biotechs is set up to stand out over the long-term.

Inovio's COVID-19 vaccine race is not run.

The more important question is: Why have Inovio's shares fallen for several weeks now?

NVAX had run over 4,000% YTD at its peak. COVID-19 vaccine hype is giving it some much-needed fuel after failing two late-stage clinical trials in 2016 and 2019.

Nevertheless, while it's not out of the running just yet, it may be best not to take a gamble with INO stock. Sit on the sidelines for now, and wait for a more compelling entry point.